The Claim

Ended federal funding for dangerous gain-of-function research in foreign countries.

The Claim, Unpacked

What is literally being asserted?

The Trump administration permanently ended federal funding for gain-of-function research conducted in foreign countries, characterizing such research as “dangerous.”

What is being implied but not asserted?

The claim implies that (1) the federal government was actively funding dangerous gain-of-function research abroad when Trump took office, (2) that ending this funding was a decisive, early action of this administration, and (3) that the COVID-19 pandemic may have resulted from U.S.-funded gain-of-function research at a foreign lab — specifically the Wuhan Institute of Virology — making this action an obvious safety measure. The word “dangerous” does double duty: it characterizes the research as inherently reckless while implicitly validating the COVID lab-leak theory.

What is conspicuously absent?

The claim omits several critical facts. First, the executive order was signed on May 5, 2025 — not on day one — over three months into the administration. Second, the order goes far beyond foreign research: it also suspended all federally funded gain-of-function research domestically, affecting at least 40 NIH-funded projects at U.S. universities and NIH’s own labs. Third, the Biden administration had already developed a comprehensive replacement framework (the 2024 DURC/PEPP policy) that was set to take effect May 6, 2025 — literally the day after Trump’s EO rescinded it. Fourth, the specific pathway the claim evokes — NIH funding to EcoHealth Alliance funneled to the Wuhan Institute of Virology — had already been terminated: NIH permanently ended the WIV subaward in August 2022, and HHS formally debarred both EcoHealth Alliance and Peter Daszak in January 2025. The problem the claim presents as being solved had already been addressed through multiple prior actions.

Evidence Assessment

Established Facts

Executive Order 14292 was signed on May 5, 2025, titled “Improving the Safety and Security of Biological Research.” The order permanently ends federal funding for gain-of-function research in “countries of concern (e.g., China)” and nations “deemed to have insufficient research oversight.” It also suspends all federally funded gain-of-function research domestically pending development of a new oversight policy within 120 days. Violations carry penalties including five-year ineligibility for federal life-sciences grants. ¹

The order defines “dangerous gain-of-function research” broadly, covering seven categories of enhancement. The definition encompasses research on any infectious agent or toxin that enhances pathogenicity, transmissibility, host range, stability, immune evasion, resistance to treatments, or ability to be weaponized. This is substantially broader than prior frameworks, which focused on “enhanced potential pandemic pathogens” (ePPP) with specific risk criteria. Many researchers and biosafety professionals have argued the definition captures routine research that has never sparked safety concerns, including tuberculosis studies. ²

The EO rescinded the 2024 DURC/PEPP policy that was scheduled to take effect May 6, 2025 — one day after the EO was signed. The Biden-era policy, released May 6, 2024, had been developed over years of interagency consultation and superseded three prior oversight frameworks (the 2012 Federal DURC Policy, the 2014 Institutional DURC Policy, and the P3CO Framework). Research institutions had invested substantial time and resources preparing for its implementation. The Trump EO replaced it with a 120-day policy development deadline. ³

The specific NIH-to-EcoHealth-to-Wuhan funding pipeline had already been terminated before this administration. NIH permanently terminated the WIV subaward in August 2022 for compliance violations, including WIV’s failure to provide laboratory notebooks. HHS suspended all federal funding to EcoHealth Alliance in May 2024 and formally debarred both EcoHealth and its president Peter Daszak on January 17, 2025 — three days before Trump’s inauguration — for facilitating gain-of-function research in Wuhan without proper oversight. The total NIH funding that reached WIV through EcoHealth was approximately $600,000 out of a $3.7 million grant over six years. ⁴

NIH suspended at least 40 domestic research projects following the EO. By June 2025, NIH had identified 40 projects potentially meeting the “dangerous gain-of-function” definition and demanded researchers suspend or modify their work. Nearly half involved tuberculosis research — a pathogen that has not traditionally raised gain-of-function concerns given that approximately one-quarter of the human population carries latent TB infection. Projects were suspended at U.S. universities and nine were conducted by NIH’s own in-house scientists. ⁵

Strong Inferences

A GAO report published January 20, 2026 found that HHS had long failed to adequately share information about its gain-of-function research risk assessments. GAO-26-107348 found HHS does not consistently disclose details about its process for weighing risks and benefits of such research, does not report the number of projects involving higher-risk pathogens to the public, and recommended HHS ensure key information on risk reviews is publicly shared with researchers, Congress, and the public. Single authoritative primary source. ⁶

The gain-of-function policy framework had documented deficiencies across administrations, making reform genuinely warranted — but the Trump approach created a policy vacuum rather than filling one. The P3CO framework (2017-2024) was widely criticized for vagueness, secrecy in its review process, and limited scope. The Biden 2024 DURC/PEPP policy addressed many of these shortcomings after years of development. The Trump EO rescinded this ready-to-implement policy and replaced it with a 120-day development mandate. As of March 2026, the 120-day deadline passed approximately September 2, 2025, and no finalized replacement policy has been publicly released, leaving research in extended limbo. ⁷

The broad definition of “dangerous gain-of-function research” appears designed to cast a wide net for political messaging rather than targeted biosafety protection. The definition in EO 14292 captures a much broader range of research than prior ePPP or DURC frameworks. Biosafety professionals and institutional review boards have reported significant confusion about which research qualifies, leading some researchers to preemptively halt work out of caution. The Bulletin of the Atomic Scientists described the timing as “incredibly disruptive” and noted institutions had spent “a lot of time and effort” preparing for the 2024 policy that was rescinded at the last moment. ⁸

The claim’s framing as ending foreign funding obscures that the primary impact has been on domestic U.S. research. The most concrete foreign funding pathway (NIH-EcoHealth-WIV) was already dead. The EO’s measurable operational impact has been the domestic research suspension: 40+ U.S. projects halted, grant applications frozen, institutional confusion. The foreign component is largely symbolic — addressing a problem already solved — while the domestic component has materially affected pandemic preparedness research including H5N1 avian influenza studies, SARS-like coronavirus research, and select agent work on Ebola and Nipah. ⁹

What the Evidence Shows

The core claim is technically accurate on its narrowest reading: Executive Order 14292 does end federal funding for gain-of-function research in foreign countries of concern. The problem the claim evokes is real — the NIH-to-EcoHealth-to-WIV funding chain was a genuine oversight failure that multiple investigations documented. The P3CO framework that governed such research from 2017 onward was widely acknowledged as inadequate, and a January 2026 GAO report confirmed HHS still had transparency deficiencies. There is a legitimate biosafety argument for restricting gain-of-function research in countries where the U.S. cannot verify safety protocols.

But the claim is misleading in several important ways. It presents as a focused foreign-policy action what is actually a sweeping domestic and international research freeze. The EO suspended all federally funded gain-of-function research in the United States — affecting at least 40 active projects at American universities and NIH’s own labs — not just foreign work. The specific foreign funding pathway that animated the controversy (NIH-to-EcoHealth-to-Wuhan) had already been terminated: the WIV subaward was cut in 2022, and EcoHealth was debarred three days before Trump took office. The Trump administration was effectively locking a door that had already been closed and bolted, while also freezing research inside the house.

The timing is equally telling. The EO was signed May 5, 2025, the day before the Biden administration’s comprehensive replacement framework — the 2024 DURC/PEPP policy, developed over years of interagency work — was scheduled to take effect. Rather than building on or strengthening this ready-to-implement framework, the administration rescinded it and imposed a 120-day deadline for a new policy. That deadline passed in September 2025. As of March 2026, no finalized replacement has been publicly released, meaning U.S. biosafety research governance has been in an extended policy vacuum — arguably less safe than the framework it replaced.

The claim also sits within a broader political context. RFK Jr. as HHS Secretary and Jay Bhattacharya as NIH director — both vocal critics of pandemic-era public health measures — brought institutional skepticism of virology research into positions of authority over its funding. The EO’s framing, particularly its use of “dangerous” as a descriptor, aligns with COVID-origins messaging that has energized the administration’s political base. The scientific community’s response has been sharply divided: biosecurity hawks welcome restrictions on foreign research, while pandemic preparedness researchers warn that halting H5N1, TB, and coronavirus studies leaves the country less prepared for the next outbreak.

The Bottom Line

The claim that the administration “ended federal funding for dangerous gain-of-function research in foreign countries” is true on its face but misleading in context. The executive order does ban such foreign funding, but the most prominent foreign pipeline (NIH-to-Wuhan) was already severed, the order also froze domestic research at 40+ U.S. institutions, it replaced a comprehensive ready-to-implement oversight framework with a policy vacuum that persists nearly a year later, and the definition of “dangerous” is broad enough to sweep in routine pathogen research. The genuine biosafety concern underlying the claim — that U.S. funds should not support inadequately supervised research in adversarial nations — was already being addressed and had bipartisan support. What the EO actually delivered was something broader and more disruptive than the claim suggests: an indefinite freeze on significant pandemic preparedness research, both foreign and domestic, with no replacement framework in place.

Footnotes

1. Executive Order 14292, “Improving the Safety and Security of Biological Research,” signed May 5, 2025. Published in Federal Register May 8, 2025 (90 FR 19611). ↩

2. Lathrop GPM analysis, “Trump Executive Order Restricts Funding for Dangerous Gain-of-Function Research,” May 2025; David R. Gillum, “A possible turning point for research governance in the life sciences,” mSphere (2025). ↩

3. Biden OSTP, “United States Government Policy for Oversight of Dual Use Research of Concern and Pathogens with Enhanced Pandemic Potential,” released May 6, 2024. ↩

4. House Oversight Committee, “HHS Formally Debars EcoHealth Alliance, Dr. Peter Daszak,” January 17, 2025; NIH terminated WIV subaward August 2022. ↩

5. Science, “Exclusive: NIH suspends dozens of pathogen studies over gain-of-function concerns,” 2025; NIH Notice NOT-OD-25-127 (June 2025). ↩

6. GAO-26-107348, “High Risk Research: HHS Should Publicly Share More Information on How Risk Is Assessed and Mitigated,” published January 20, 2026. ↩

7. CRS reports R47114 and IN12554; GAO-23-105455; mSphere article (PMC12379582). ↩

8. Bulletin of the Atomic Scientists, “Trump’s last minute gain-of-function policy could sow researcher confusion,” May 2025. ↩

9. Global Biodefense, “How the Trump Administration’s Ban on Gain-of-Function Research Undermines Pandemic Preparedness,” May 2025; NPR, “Trump restricts funding for controversial gain-of-function research,” May 5, 2025. ↩